Navigation Links
MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
Date:8/23/2007

New Facility Allows MedImmune to Meet Increasing Demands for Clinical Trial

Materials from Company's Expanding and Advancing Pipeline

GAITHERSBURG, Md., Aug. 23 /PRNewswire-FirstCall/ -- MedImmune today unveiled a new, state-of-the-art pilot lab facility located on the same Gaithersburg site as its headquarters. With its cutting-edge equipment and process automation systems, the facility will support MedImmune's expanding clinical product pipeline by providing additional capacity and flexibility.

At a ribbon-cutting event for the pilot lab held today at MedImmune, David M. Mott, president and chief executive officer, stated: "Completing this new facility is an important milestone, signaling our continued growth and success as a world-class biopharmaceuticals company. The opening of this facility, alongside the expansion work underway on our new biologics facility in Frederick, Maryland, reaffirms our leadership role within the state's biotechnology industry and demonstrates our ongoing commitment to the region."

The new pilot lab's 5,000 liters of bioreactor capacity will result in a four-fold increase in production capabilities. With the expanded facility, MedImmune will be able to produce clinical trial materials at a greater scale and in greater quantities, aiding in the testing of potential new products.

"This substantial increase in MedImmune's clinical production infrastructure supports our robust pipeline of product candidates," said Gail Folena-Wasserman, Ph.D., senior vice president, development. "The pilot lab facility is intended to meet our current and future needs, not just through its increased capacity but also through design flexibility, which efficiently allows us to produce multiple clinical products in the same space. We can drive efficiency and meet rigorous quality standards by incorporating the latest technology, including an advanced process control system."

In December 2006, the City of Gaithersburg approved the new pilot lab facility for occupancy. The facility will become the primary site for production of MedImmune's therapeutic proteins, replacing the existing Gaithersburg Manufacturing Development Facility (GMDF) where those clinical trial materials are currently produced. Material production is expected to begin in 2008, following the final stages of equipment validation. MedImmune plans to upgrade GMDF in the near future to provide added support for its development needs.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Why Files celebrates decade of science exploration
2. Young Professionals of Milwaukee Celebrates Its Third Birthday, Looks To The Future
3. Internet Scout celebrates 10 years on web, eyes new project launch
4. Farm Aid celebrates 20-year journey, heads back to Illinois roots
5. UW Office of Corporate Relations Celebrates Early Accomplishments
6. Its All Fun And Games in Madison - Raven Software Celebrates 15 Anniversary
7. Merge files financial reports by market opening
8. RFID pilot project aims to improve blood banks
9. Pilot fund brings capital to Eau Claire area innovations
10. National $100m pilot program to begin mapping cancer genome
11. Milwaukee health provider network pilots software plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Energetiq Technology, a ... a facility expansion to accommodate its rapid growth. , The renovations at the ... renovation of the existing areas. The expansion includes, a state-of-the-art engineering facility, and ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... machine manufacturers to re-engineer their control technology again and again. METTLER TOLEDO has ... for machine manufacturers. The videos illustrate how integration of the ACT350 into Siemens ...
(Date:5/21/2017)... , ... May 19, 2017 , ... ... and educational conference of the American Association of Bioanalysts (AAB) and the College ... in Houston. The conference reinforces AAB’s commitment to excellence in clinical laboratory services ...
(Date:5/18/2017)... ... 18, 2017 , ... Dr. Ralph Mobbs of the Neuro ... Wales Private Hospital. The procedure was performed on a 46-year-old male patient suffering ... prior to undergoing surgery. , The AxioMed viscoelastic disc is a next-generation disc ...
Breaking Biology Technology:
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):